Free Trial

AC Immune (ACIU) Competitors

AC Immune logo
$2.46 -0.08 (-3.15%)
Closing price 09/17/2025 04:00 PM Eastern
Extended Trading
$2.51 +0.05 (+2.03%)
As of 05:55 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ACIU vs. IMNM, AMLX, IOVA, PHAT, URGN, TRVI, DNTH, AVBP, AVXL, and ABUS

Should you be buying AC Immune stock or one of its competitors? The main competitors of AC Immune include Immunome (IMNM), Amylyx Pharmaceuticals (AMLX), Iovance Biotherapeutics (IOVA), Phathom Pharmaceuticals (PHAT), Urogen Pharma (URGN), Trevi Therapeutics (TRVI), Dianthus Therapeutics (DNTH), ArriVent BioPharma (AVBP), Anavex Life Sciences (AVXL), and Arbutus Biopharma (ABUS). These companies are all part of the "pharmaceutical products" industry.

AC Immune vs. Its Competitors

AC Immune (NASDAQ:ACIU) and Immunome (NASDAQ:IMNM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

In the previous week, AC Immune and AC Immune both had 3 articles in the media. Immunome's average media sentiment score of 1.60 beat AC Immune's score of 1.38 indicating that Immunome is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AC Immune
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Immunome
2 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

AC Immune has a net margin of -174.94% compared to Immunome's net margin of -1,687.08%. AC Immune's return on equity of -49.35% beat Immunome's return on equity.

Company Net Margins Return on Equity Return on Assets
AC Immune-174.94% -49.35% -23.16%
Immunome -1,687.08%-76.10%-65.14%

AC Immune currently has a consensus target price of $10.00, suggesting a potential upside of 306.50%. Immunome has a consensus target price of $22.89, suggesting a potential upside of 154.60%. Given AC Immune's higher possible upside, equities analysts clearly believe AC Immune is more favorable than Immunome.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AC Immune
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
Immunome
0 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
3.00

AC Immune has higher revenue and earnings than Immunome. AC Immune is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AC Immune$31.02M7.96-$57.83M-$0.58-4.24
Immunome$9.04M86.56-$292.96M-$3.08-2.92

AC Immune has a beta of 1.61, indicating that its share price is 61% more volatile than the S&P 500. Comparatively, Immunome has a beta of 1.92, indicating that its share price is 92% more volatile than the S&P 500.

51.4% of AC Immune shares are owned by institutional investors. Comparatively, 44.6% of Immunome shares are owned by institutional investors. 4.6% of AC Immune shares are owned by company insiders. Comparatively, 7.7% of Immunome shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

AC Immune beats Immunome on 8 of the 15 factors compared between the two stocks.

Get AC Immune News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACIU and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACIU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ACIU vs. The Competition

MetricAC ImmuneMED IndustryMedical SectorNASDAQ Exchange
Market Cap$255.04M$3.12B$5.74B$10.30B
Dividend YieldN/A2.37%5.86%4.62%
P/E Ratio-4.2421.0376.8526.52
Price / Sales7.96249.02453.0387.93
Price / CashN/A45.4837.2260.63
Price / Book1.919.5613.686.31
Net Income-$57.83M-$53.02M$3.29B$271.37M
7 Day Performance3.36%-1.58%-0.75%0.57%
1 Month Performance14.42%2.82%3.84%6.20%
1 Year Performance-32.23%9.34%82.85%28.33%

AC Immune Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ACIU
AC Immune
2.6478 of 5 stars
$2.46
-3.1%
$10.00
+306.5%
-28.9%$255.04M$31.02M-4.24140Positive News
IMNM
Immunome
2.2168 of 5 stars
$9.40
-10.6%
$22.89
+143.5%
-41.6%$915.71M$9.04M-3.0540Positive News
AMLX
Amylyx Pharmaceuticals
2.3218 of 5 stars
$10.44
+2.4%
$12.25
+17.3%
+337.3%$909.51M$87.37M-4.18200Analyst Forecast
IOVA
Iovance Biotherapeutics
4.3331 of 5 stars
$2.38
-4.4%
$11.90
+400.0%
-78.7%$901.02M$164.07M-1.93500
PHAT
Phathom Pharmaceuticals
2.3936 of 5 stars
$12.43
+0.7%
$17.50
+40.8%
-40.5%$875.45M$55.25M-2.63110
URGN
Urogen Pharma
4.0906 of 5 stars
$21.42
+13.5%
$32.00
+49.4%
+41.0%$873.47M$90.40M-6.45200Positive News
High Trading Volume
TRVI
Trevi Therapeutics
2.8392 of 5 stars
$7.60
+8.4%
$21.75
+186.2%
+139.6%$853.66MN/A-18.0920Positive News
High Trading Volume
DNTH
Dianthus Therapeutics
2.9109 of 5 stars
$31.80
+20.0%
$54.00
+69.8%
+49.6%$852.99M$6.24M-9.7880Gap Up
High Trading Volume
AVBP
ArriVent BioPharma
2.0182 of 5 stars
$20.21
+0.1%
$39.14
+93.7%
-26.9%$819.09MN/A-5.0340Positive News
AVXL
Anavex Life Sciences
3.6756 of 5 stars
$9.35
-0.5%
$44.00
+370.6%
+60.8%$807.40MN/A-16.4040Positive News
ABUS
Arbutus Biopharma
1.9864 of 5 stars
$4.09
-2.6%
$5.00
+22.2%
+8.6%$805.13M$6.17M-14.1090

Related Companies and Tools


This page (NASDAQ:ACIU) was last updated on 9/18/2025 by MarketBeat.com Staff
From Our Partners